Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Hydroxychloroquine in COVID-19 ICU Patients
NCT04522466Phase 3Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19), sponsored by CHU Saint-Etienne. Primary endpoint: Pharmacokinetics of hydroxychloroquine (HCQ). Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04522466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522466.